LNZA — LanzaTech Global, Inc.

Summary of LanzaTech Global Inc. Q3 2024 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $9.9 million, significantly below the target by approximately $7 million.
  • Biorefining Revenues: $5.9 million, similar to Q2 but down $6.5 million year-over-year.
  • Joint Development Agreements and Contract Research: $1.8 million, down from $2.8 million in Q2.
  • CarbonSmart Product Sales: $2.2 million, up from $0.9 million in Q2.
• Gross Margin: 18% of revenue, impacted by lower-margin sales and absence of high-margin LanzaJet share revenue.
• Operating Expenses: $34.8 million, up $5 million year-over-year but flat compared to Q2.
• Adjusted EBITDA Loss: $27.1 million, compared to a loss of $19.1 million in Q3 2023.
• Cash Position: $89.1 million at the end of September, up from $75.8 million in Q2, bolstered by a $40 million investment from Carbon Direct Capital.

2. Strategic Updates and Business Highlights:

• Business Model Evolution: Transitioning from a licensing-focused model to developing and financing own projects to capture more value and control over timelines.
• Project Developments:
  • Project Drake: A significant ethanol-to-sustainable aviation fuel (SAF) project nearing final investment decision (FID) with a $5 million exclusivity fee received.
  • Norwegian Project: Expected to reach FID soon, potentially generating $20 million in revenue.
  • Joint Venture with Olayan Group: Focused on expanding commercial opportunities in the Middle East.
• New Product Launch: Introduction of LanzaTech Nutritional Protein, targeting the alternative protein market.
• Ethanol Off-take Agreement with ArcelorMittal: Two-stage agreement projected to generate $6 million to $20 million annually.

3. Forward Guidance and Outlook:

• Q4 2024 Expectations: Anticipated revenue drivers include:
  • Base business generating approximately $10 million.
  • Potential $20 million from the Norwegian project upon positive FID.
  • Additional revenue from Project Drake and Project SECURE.
  • Possible revenue from LanzaJet sublicensing agreements.
• Long-term Growth: Confidence in 2025 and beyond, driven by evolving business model and project pipeline.

4. Bad News, Challenges, or Points of Concern:

• Revenue Shortfall: Q3 revenue significantly below expectations due to delays in LanzaJet sublicensing agreements and depressed ethanol pricing.
• Increased Operating Costs: While expenses are controlled, project development costs are high, impacting profitability.
• Market Dynamics: Challenges in ethanol pricing affecting CarbonSmart sales and overall revenue generation.
• Timing Uncertainty: Multiple projects have uncertain timelines, leading to potential volatility in revenue recognition.

5. Notable Q&A Insights:

• Project Drake Revenue: The $5 million received is expected to be recognized as revenue in Q4, separate from the base business revenue.
• Cost Control Initiatives: Despite rising operating costs, management is focused on reducing specific expenses while incurring costs for project development.
• Infrastructure Partnerships: LanzaTech is exploring multiple partnerships beyond Brookfield to finance projects, enhancing flexibility and capital access.
• Nutritional Protein Production: The product is 85% protein with all essential amino acids, and while nitrogen must be added, the carbon intensity is significantly lower compared to traditional animal protein sources.
• Market Interest: Strong interest from emitters and infrastructure partners in low-carbon projects, indicating a favorable environment for future growth.

Overall, LanzaTech is navigating challenges in revenue generation and cost management while strategically positioning itself for future growth through project development and new product offerings.